Richard Chin, M.D. is the Chief Executive Officer of OneWorld Health, a nonprofit pharmaceutical company largely funded by the Bill and Melinda Gates Foundation, developing drugs for impoverished patients in the developing world. Previously, Dr. Chin held multiple senior positions in several biotechnology companies and has extensive expertise in drug development including 10 new drug registrations filings/launches and over 45 Investigational New Drug (IND) Applications. Some of the drugs he has overseen include Rituxan, Lucentis, Tysabri, TNKase, Raptiva, Xolair, Cathflo, Prialt, Protropin, Nutropin, Pulmo- zyme, Azactam, Maxipime, and Bapineuzumab, among others. Dr. Chin was named by Businessweek in 2006 as one of the youngest 99 public company CEOs in the United States. Dr. Chin earned his M.D. from Harvard and the equivalent of a J.D. from Oxford, where he studied as a Rhodes Scholar. Dr. Chin serves as Associate Professor at UCSF School of Medicine and was previously on the adjunct faculty at Stanford University School of Medicine.

"For the past few decades, adaptive clinical trials (ACT) have been enjoying increasing popularity and attention in biomedical research and industry ... what was lacking was a 'real' book that would summarize these techniques to a wider audience. Dr. Richard Chin fills this void with his commendable book ... The book is nicely written and lucid, with a proper sequencing of concepts." -Journal of the American Statistical Association, December 2013 "... later chapters in the book ... are most useful. They describe the various types of adaptations that can be used. ... This book is helpful for a starter in adaptive designs, to get an idea of the visions behind applying such designs." -Philip Hougaard and Corine Baayen, ISCB Newsletter, June 2013

• Background. Background: Conventional Statistics. Statistics Used in Adaptive Clinical Trials. Specific Requirements for Adaptive Trials. Adaptive Randomization and Allocation. Sample Size Reestimation. Traditional Dosing. Adaptive Dosing. Interim Analysis and Adaptive Termination of Study and Study Arms. Adaptive Changes in Study Design and Decision Rules. Seamless Designs and Adaptive Clinical Trial Conduct. Analysis and Interpretation of Results. Index.

Richard Chin, M.D. is the Chief Executive Officer of OneWorld Health, a nonprofit pharmaceutical company largely funded by the Bill and Melinda Gates Foundation, developing drugs for impoverished patients in the developing world. Previously, Dr. Chin held multiple senior positions in several biotechnology companies and has extensive expertise in drug development including 10 new drug registrations filings/launches and over 45 Investigational New Drug (IND) Applications. Some of the drugs he has overseen include Rituxan, Lucentis, Tysabri, TNKase, Raptiva, Xolair, Cathflo, Prialt, Protropin, Nutropin, Pulmo- zyme, Azactam, Maxipime, and Bapineuzumab, among others. Dr. Chin was named by Businessweek in 2006 as one of the youngest 99 public company CEOs in the United States. Dr. Chin earned his M.D. from Harvard and the equivalent of a J.D. from Oxford, where he studied as a Rhodes Scholar. Dr. Chin serves as Associate Professor at UCSF School of Medicine and was previously on the adjunct faculty at Stanford University School of Medicine.

"For the past few decades, adaptive clinical trials (ACT) have been enjoying increasing popularity and attention in biomedical research and industry ... what was lacking was a 'real' book that would summarize these techniques to a wider audience. Dr. Richard Chin fills this void with his commendable book ... The book is nicely written and lucid, with a proper sequencing of concepts." -Journal of the American Statistical Association, December 2013 "... later chapters in the book ... are most useful. They describe the various types of adaptations that can be used. ... This book is helpful for a starter in adaptive designs, to get an idea of the visions behind applying such designs." -Philip Hougaard and Corine Baayen, ISCB Newsletter, June 2013

• Background. Background: Conventional Statistics. Statistics Used in Adaptive Clinical Trials. Specific Requirements for Adaptive Trials. Adaptive Randomization and Allocation. Sample Size Reestimation. Traditional Dosing. Adaptive Dosing. Interim Analysis and Adaptive Termination of Study and Study Arms. Adaptive Changes in Study Design and Decision Rules. Seamless Designs and Adaptive Clinical Trial Conduct. Analysis and Interpretation of Results. Index.

Richard Chin, M.D. is the Chief Executive Officer of OneWorld Health, a nonprofit pharmaceutical company largely funded by the Bill and Melinda Gates Foundation, developing drugs for impoverished patients in the developing world. Previously, Dr. Chin held multiple senior positions in several biotechnology companies and has extensive expertise in drug development including 10 new drug registrations filings/launches and over 45 Investigational New Drug (IND) Applications. Some of the drugs he has overseen include Rituxan, Lucentis, Tysabri, TNKase, Raptiva, Xolair, Cathflo, Prialt, Protropin, Nutropin, Pulmo- zyme, Azactam, Maxipime, and Bapineuzumab, among others. Dr. Chin was named by Businessweek in 2006 as one of the youngest 99 public company CEOs in the United States. Dr. Chin earned his M.D. from Harvard and the equivalent of a J.D. from Oxford, where he studied as a Rhodes Scholar. Dr. Chin serves as Associate Professor at UCSF School of Medicine and was previously on the adjunct faculty at Stanford University School of Medicine.

"For the past few decades, adaptive clinical trials (ACT) have been enjoying increasing popularity and attention in biomedical research and industry ... what was lacking was a 'real' book that would summarize these techniques to a wider audience. Dr. Richard Chin fills this void with his commendable book ... The book is nicely written and lucid, with a proper sequencing of concepts." -Journal of the American Statistical Association, December 2013 "... later chapters in the book ... are most useful. They describe the various types of adaptations that can be used. ... This book is helpful for a starter in adaptive designs, to get an idea of the visions behind applying such designs." -Philip Hougaard and Corine Baayen, ISCB Newsletter, June 2013

• Background. Background: Conventional Statistics. Statistics Used in Adaptive Clinical Trials. Specific Requirements for Adaptive Trials. Adaptive Randomization and Allocation. Sample Size Reestimation. Traditional Dosing. Adaptive Dosing. Interim Analysis and Adaptive Termination of Study and Study Arms. Adaptive Changes in Study Design and Decision Rules. Seamless Designs and Adaptive Clinical Trial Conduct. Analysis and Interpretation of Results. Index.